Journal Manager Demo for Scholarly Journals
Nominations for the 2026 Best Paper Award are open until 30 September. Any research article published in the journal during 2026 is eligible. Nominations may be submitted by readers, reviewers or editorial board members.
We invite submissions for a themed collection on single-cell approaches to tumour evolution. Contributions addressing lineage tracing, spatial transcriptomics and computational…
Following changes to our editorial workflow, median time from submission to first decision has fallen to 18 days, down from 34 days in 2024. Desk decisions are now issued within 5 working…
The journal now accepts Registered Reports, in which study protocols are peer reviewed before data collection begins. Accepted protocols receive in-principle acceptance independent of…
A special issue on cancer epigenetics will be guest edited by Dr Ingrid Moreau. Topics include DNA methylation biomarkers, chromatin remodelling in progression, and epigenetic therapy.
Our forthcoming special issue focuses on liquid biopsy technologies for early cancer detection, covering assay development, clinical validation and health-economic evaluation.
The journal has been accepted for indexing in Scopus and PubMed Central. All content published from volume 1 onwards will be retrospectively deposited.
From 1 August 2026, all articles reporting primary genomic data must deposit raw sequence data in a recognised public repository and include an accession number in the data availability…
We are expanding our reviewer pool in cancer genomics, computational biology and clinical oncology. Reviewers receive formal recognition and an annual certificate of contribution.
We welcome twelve new members to the editorial board for 2026, bringing expertise in single-cell genomics, epigenetics, immuno-oncology and biostatistics.
